August 11, 2025: NEUREGEN's NRG-103, the world's first in situ transdifferentiation-based gene therapy for glioblastoma, received FDA IND approval, with non-clinical support from InnoStar aiding the approval.
InnoStar and Cyberiad-Life developed a 3D-bioprinted mouse testicular organoid model, enabling in vitro reproductive toxicity screening, featured in ACS Biomater. Sci. Eng.
InnoStar launches its 24,000 sqm Nantong Phase II Non-Clinical Evaluation Platform in China, featuring 130 animal rooms to ease capacity constraints and accelerate drug development.
InnoStar Nantong Facility Successfully Passed U.S. FDA GLP Inspection
Address: 199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, China
Postcode: 201203
Tel: +86-21-60211999
services@innostarbio.com
86-021-xxxxxxx
Scan the QR code
Subscription to our Wechat account
Copyright © 2017-2021©Shanghai InnoStar Bio-tech Co., Ltd. All Rights Reserved. Created By VPABrand.com
